A COMBINATION CHEMOENDOCRINE THERAPY OF MITOXANTRONE, DOXIFLURIDINE, AND MEDROXYPROGESTERONE ACETATE FOR ANTHRACYCLINE-RESISTANT ADVANCED BREAST-CANCER

Citation
Y. Iino et al., A COMBINATION CHEMOENDOCRINE THERAPY OF MITOXANTRONE, DOXIFLURIDINE, AND MEDROXYPROGESTERONE ACETATE FOR ANTHRACYCLINE-RESISTANT ADVANCED BREAST-CANCER, Cancer chemotherapy and pharmacology, 41(3), 1998, pp. 243-247
Citations number
47
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology & Pharmacy",Oncology
ISSN journal
0344-5704
Volume
41
Issue
3
Year of publication
1998
Pages
243 - 247
Database
ISI
SICI code
0344-5704(1998)41:3<243:ACCTOM>2.0.ZU;2-I
Abstract
Between January 1993 and October 1995, 34 patients with anthracycline- resistant advanced breast cancer were treated with a combination chemo endocrine therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and m edroxyprogesterone acetate (MPA). Of 34 patients, 28 were evaluable fo r efficacy of this combination therapy, and 30 including 2 for whom da ta were incomplete were assessed for adverse drug reactions. Adriamyci n (ADM) was used for pretreatment in 12 patients, 4'-epi-ADM in 6, and THP-ADM in 12. In the eligible patients, 8.0 mg/m(2) MIT was administ ered intravenously every 4 weeks, and 600 mg MPA and 600 mg 5'-DFUR we re given orally every day. The median follow-up period was 25 weeks (r ange 2-90 weeks). The median cumulative dose of mitoxantrone was 66 mg (range 12-121 mg). Of the 28 patients, 11 (39.3%) responded to this c ombination therapy. As for response in relation to predominant site of lesion, 1 of 5 soft tissue lesions (20%) and 8 of 12 bone metastases (66.7%) showed a partial response, and one complete response and one p artial response (25.0%) were seen in eight lung lesions. None of three pleural lesions responded to this therapy. The median duration of res ponse was 31 +/- weeks (range 12-82 weeks). Adverse drug reactions wer e controllable or tolerable. Combined chemoendocrine therapy with a lo w dose of MIT is a well-tolerated and moderately effective regimen for the treatment of anthracycline-resistant advanced breast cancer.